Association Between a National Insurer’s Pay-for-Performance Program for Oncology and Changes in Prescribing of Evidence-Based Cancer Drugs and Spending

October 6, 2020

Journal of Clinical Oncology

Read the full article

Authors

Justin E. Bekelman, Atul Gupta, Ezra Fishman, David Debono, Michael J. Fisch, Ying Liu, Gosia Sylwestrzak, John Barron, and Amol S. Navathe

CHIBE Experts

Research Areas

Implementation of a Secure Firearm Storage Program in Pediatric Primary Care: A Cluster Randomized Trial

JAMA Pediatrics

September 19, 2024
Skepticism Calibration Disorder—The New Public Health Crisis

JAMA Network Open

September 4, 2024
Using Behavioral Science to Improve Cardiovascular Health

AHA Journals

September 3, 2024
Emergency Medicaid enrollment after traumatic injury predicts long-term health care utilization

Journal of Trauma and Acute Care Surgery

September 3, 2024
Clinician Specialty and HIV PrEP Prescription Reversals and Abandonments

JAMA Network

August 19, 2024
Protocol for a type 3 hybrid implementation cluster randomized clinical trial to evaluate the effect of patient and clinician nudges to advance the use of genomic medicine across a diverse health system

Implementation Science

August 19, 2024
Looking to "Level the Field": A Qualitative Study of How Clinicians Operationalize Social Determinants in Critical Care

Annals of the American Thoracic Society

August 6, 2024
Hospice Administrators' and Providers' Perspectives on Providing Upstream Palliative Care: Facilitators, Barriers, and Policy Prescriptions

Journal of Palliative Medicine

July 29, 2024
Increasing goals of care conversations in primary care: Study protocol for a cluster randomized, pragmatic, sequential multiple assignment randomized trial

Contemporary Clinical Trials

July 27, 2024
Clinician- and Patient-Directed Communication Strategies for Patients With Cancer at High Mortality Risk

JAMA Network Open

July 1, 2024
Clinicians' Use of Choice Framing in ICU Family Meetings

Critical Care Medicine

June 24, 2024
Formulary Coverage of Brand-Name Adalimumab and Biosimilars Across Medicare Part D Plans

JAMA Network

June 6, 2024